Pretomanid

Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual operating results (the reporting period). Powered by the dual engines of innovation and globalization, Fosun Pharma achieved total operating revenue of RMB 41.662 billion, up 1.45% year-on-year. Of this, revenue from innovative drugs reached RMB 9.893 billion, rising 29.59% year-on-year; overseas revenue amounted to RMB 12.977 billion, growing 14.87% year-on-year. Net profit attributable to shareholders of the parent company was RMB 3.371 billion, up 21.69% year-on-year; recurring net profit attributable to shareholders of the parent company amounted to RMB 2.34 billion, increasing 1.12% year-on-year; and net cash flow generated from operating activities reached RMB 5.213 billion, up 16.45% year-on-year, further consolidating the foundation for high-quality development. Innovative Drugs Emerge as Core Growth Engine Revenue from innovative drugs hit RMB 9.893 billion, accounting for 33.16% of pharmaceutical business revenue, becoming the core engine of performance growth. Total R&D investment for the year amounted to RMB 5.913 billion, up 6.46% year-on-year, of which R&D investment related to innovative pharmaceuticals reached RMB 4.303 billion, a year-on-year increase of 15.98%, accounting for 80.26% of pharmaceutical business R&D investment. High-intensity R&D investment has been translated into fruitful results. During the reporting period, 16 indications of 7 innovative drugs were approved for marketing in China and overseas markets; marketing applications for 6 innovative drug candidates were accepted, and nearly 40 innovative drug clinical trials received approval from China and overseas regulatory authorities; and multiple core products entered key clinical phases, laying a solid pipeline foundation for subsequent commercial growth. Additionally, 5 new innovative drugs were included in the 2025 National Reimbursement Drug List (NRDL), and the CAR-T therapy Yikaida (axicabtagene ciloleucel injection) was successfully listed in the first edition of the Commercial Insurance Innovative Drug Catalog. This not only improves patient access to innovative drugs but also further unlocks the volume potential of commercialization. Building Differentiated Clinical Pipeline Advantages Fosun Pharma focuses on innovative drugs as its development priority. Centering on the three core therapeutic areas of oncology (solid tumors, hematologic tumors), immune inflammation and neurodegenerative diseases, the Company continuously strengthens its pipeline construction through in-house R&D, collaborative development and licensing-in. Oncology: In 2025, Fosun Pharma further strengthened the layout of its innovative pipeline around key indications such as breast cancer and lung cancer. The company's self-developed small-molecule innovative drug Fumaining® (luvometinib Tablet) received approval for two indications, filling the gap in the treatment of rare tumors in China; the innovative small-molecule CDK4/6 inhibitor Futuoning® (fovinaciclib citrate capsules) was launched for two indications in China, bringing a brand-new treatment option for breast cancer patients; the anti-PD-1 monoclonal antibody Serplulimab Injection was approved in Europe and multiple emerging markets for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), becoming the first anti-PD-1 monoclonal antibody to receive such approval in the EU and accelerating the company's globalization pace; antibody and ADC drugs such as HLX43 and HLX22 entered key clinical phases, continuously improving the echelon of the oncology pipeline. The marketing application for the second CAR-T product Brexucabtagene Autoleucel was accepted. Immune Inflammation and Chronic Diseases: The licensed-in first-in-class innovative drug Wantile (Tenapanor Hydrochloride Tablets) was successfully approved, providing a new treatment option for chronic kidney disease patients on dialysis in China. Steady clinical progress was made for core products such as FXS7553. Neurodegenerative diseases: Opicapone Capsules, a treatment for Parkinson's disease, was launched in the Boao Pilot Zone for innovative drugs. Fosun Insightech accelerated product upgrading and indication expansion for its Magnetic Resonance-guided Focused Ultrasound (MRgFUS) system. Sodium Oligomannate Capsule was incorporated into the Company's Alzheimer's disease innovative drug pipeline, with post-marketing confirmatory clinical trials underway. AR1001, an in-licensed asset, has advanced into global multi-center Phase 3 clinical trials. These initiatives further enriched the Company's product pipeline in the neurodegenerative disease sector. Breakthroughs in Cutting-Edge Technologies and Two-way Licensing On the basis of consolidating core technology platforms including antibodies, ADCs, small molecules, and cell therapy, Fosun Pharma is strategically investing in advanced fields such as radiopharmaceuticals and small interfering RNA (siRNA). The radiopharmaceutical project SRT-007 successfully initiated Phase I clinical trials, establishing a preliminary "imaging diagnosis - targeted therapy" integrated R&D pathway; in cell therapy, the autologous dual-target CAR-T product FKC289 had its clinical trial application accepted by the NMPA, continuously empowering the reserve of follow-on innovative products. In 2025, Fosun Pharma's global resource integration capability has been significantly enhanced. The total upfront payment from out-licensing reached over US$260 million in the whole year, with potential milestone payments exceeding US$ 3.8 billion. Among them, the global licensing project of the GLP-1 target YP05002 garnered an upfront payment of US$150 million and potential total payments of US$2.085 billion, fully confirming the global competitiveness of the company's innovative R&D. In terms of collaborative development, Fosun Pharma entered into a joint development agreement with Teva for FXB0871 and established original innovation cooperation with a fund under Aditum Bio. Meanwhile, Fosun Pharma introduced multiple overseas original drugs, including Akynzeo (netupitant and palonosetron hydrochloride capsules), Pu Rui Ni (pretomanid tablets) , and Daxxify (botulinum toxin type A for injection), through licensing-in, achieving marketing approval for them in China. Globalization Moves Towards "System-centric Globalization" In 2025, Fosun Pharma's international development achieved a strategic upgrade from "product-centric going global" to "system-centric globalization", making comprehensive breakthroughs in innovative R&D, production quality, registration and access, commercialization and academic influence, and building a global operation network covering markets such as China, the United States, Europe, Africa, India and Southeast Asia. In 2025, the company's overseas revenue reached RMB 12.977 billion, accounting for 31.15% of the total revenue, increased by 3.64 percentage points year-on-year. Fosun Pharma has built a global R&D and production synergy registration capability featuring "leading breakthroughs in Europe and the US, and in-depth cultivation in emerging markets". The core innovative drug Serplulimab Injection has been approved for marketing in more than 40 countries and regions worldwide. In the United States, the bridging study for first-line ES-SCLC has completed enrolment, with a Biologics License Application (BLA) submission planned for 2026. Biosimilars such as Denosumab have successively obtained approvals from the FDA and the EU, marking that the quality system and registration capability of the biologic drug platform have been certified to international standards; the small-molecule innovative drug Fumaining® received Priority Review status from the Saudi Food and Drug Authority (SFDA) in Saudi Arabia, becoming an important fulcrum to leverage the Middle East and global markets. Seventeen of Fosun Pharma's workshops/production lines in China have passed GMP certifications of mainstream regulatory markets such as the US, the EU and the WHO. The relevant biologic drug production lines have realized regular supply to the global market, covering China, Europe, Latin America, Southeast Asia, India and other markets. Multiple injection production lines of India's Gland Pharma have passed certifications in Europe, the US, Japan and Australia, providing a solid guarantee for the stability and quality controllability of the global supply chain. Fosun Pharma has formed a mature overseas go-global model of "independent operation + licensing authorization" running in parallel, with over 6,000 commercial personnel worldwide and established a marketing network covering over 40 countries and regions in Africa; the controlling subsidiary Sisram's marketing network covers over 110 countries and regions, while Breas covers over 50 countries and regions. ESG Governance Recognized by Global Authorities While achieving high-quality development of its core business, in 2025, Fosun Pharma's MSCI ESG rates were upgraded to "AA", retained its Hang Seng ESG rating of "A-" and was selected into the 2025 Fortune China ESG Influence List, being the only Chinese pharmaceutical enterprise on the list. "In 2025, Fosun Pharma firmly implemented its corporate strategy of Innovation Driven, Deep Globalization and AI Embracement, achieving high-quality growth powered by innovative drugs and globalization." Chen Yuqing, Chairman of Fosun Pharma said, "Looking ahead, Fosun Pharma will always focus on unmet clinical needs, continue to innovate, and further deepen its layout in core therapeutic areas such as oncology, immune inflammation and neurodegenerative diseases. It will integrate innovative resources from a global perspective, drive operational upgrading with digital intelligence, and strive to become a world-leading integrator of medical innovation, creating long-term value for shareholders and providing more high-quality and accessible medicines and healthcare solutions for patients." About Fosun Pharma Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem. Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia. Looking ahead, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health. For more information, please visit the company website: SOURCE Fosun Pharma 21% more press release views with Request a Demo

WOIPPY, FRANCE, March 20, 2026 / EINPresswire.com / -- ABL Diagnostics (FR001400AHX6 – “ABLD”), an innovative company specialized in microbiology and pathogen sequencing, today announced major advancements in its Mycobacterium tuberculosis (MTB) portfolio, combining its current CE-IVD marked DeepChek ® Assay 13‑Plex KB and BacterioChek software with the development of new research next‑generation sequencing (NGS) solutions for comprehensive drug resistance detection and genomic surveillance. At the core of its current offering, ABL Diagnostics commercializes the CE-IVD marked DeepChek ® Assay 13-Plex KB Drug Susceptibility Testing assay, a multiplex PCR solution enabling the detection of key resistance-associated mutations across first- and second-line anti-TB drugs. Designed for use with NGS workflows, the assay supports amplification of MTB DNA directly from clinical specimens and provides actionable genotyping data to guide treatment decisions. This solution is complemented by BacterioChek, ABL Diagnostics’ CE-IVD software for automated analysis and interpretation of MTB Next-Generation Sequencing data, delivering standardized and clinically relevant reports to support laboratories and clinicians. Building on this integrated workflow, ABL Diagnostics has developed two new solutions intended for research use for now: - A 19-gene resistance panel, expanding coverage beyond the current DeepChek ® Assay 13-Plex but with the same input DNA extraction and using the same PCR cycling program, ensuring seamless adoption for existing users. This panel already covers the full set of genes known to be associated with resistance to currently prescribed anti-tuberculosis drugs. These include first and second line treatments such as rifampicin (rpoB), isoniazid (katG, inhA), ethambutol (embB), pyrazinamide (pncA), fluoroquinolones (gyrA, gyrB), aminoglycosides such as amikacin and kanamycin (rrs, eis), as well as newer and repurposed drugs like linezolid (rplC, rrl) and bedaquiline (atpE, Rv0678). By integrating an expanded set of resistance‑associated genes, the 19‑gene panel delivers broader and more informative insights into MTB drug resistance profiles, supporting ongoing research on emerging therapeutic targets and contributing to the development of next‑generation strategies for improved disease management. - A whole genome MTB solution (~4.4 Mb) based on capture technology, enabling broad exploration of resistance associated mutationsand supporting high-resolution epidemiological and transmission studies. Beyond addressing current research needs, this whole genome approach offers a forward looking platform capable of uncovering resistance mechanisms related to both established and emerging therapeutic options. This includes next-generation agents such as bedaquiline, delamanid, pretomanid, and linezolid, as well as future compounds under development. By capturing the full genomic landscape of MTB, this solution provides an adaptable foundation for ongoing research Both solutions will be commercialized for research use only from Q2 2026. ABL Diagnostics is actively seeking partner laboratories for verification and validation studies. The regulatory roadmap will then progressively evaluate potential future CE IVD marking under the new EU IVD regulation and WHO review process. Tuberculosis remains one of the leading infectious diseases worldwide, with significant unmet medical needs driven by the growing burden of drug-resistant forms. These trends are consistent with data from the U.S. CDC TB Surveillance Report , which highlights evolving resistance patterns in recent isolates. According to recent global estimates, hundreds of thousands of new multidrug-resistant (MDR) and rifampicin-resistant TB cases are reported annually, with treatment success rates remaining substantially lower than for drug-susceptible TB. In addition, surveillance data highlights the continued emergence of resistance to key drug classes, including fluoroquinolones and second-line injectable agents, further complicating treatment strategies. ( https://www.cdc.gov/tb-surveillance-report-2024/data/drug-resistance.html ) The global market for drug-resistant tuberculosis diagnosis and treatment is expanding rapidly, driven by increasing incidence, the complexity and cost of treatment regimens, and strong support from public health organizations and funding bodies. Market growth projections are supported by recent industry analyses (HTF Market Insights, “Drug Resistant Tuberculosis Treatment Market”). Market analysts project sustained growth over the coming years, fueled by the adoption of advanced molecular diagnostics and sequencing technologies that enable faster, more accurate, and scalable resistance profiling. The adoption of NGS in clinical microbiology is accelerating this shift toward comprehensive resistance profiling and genomic surveillance, enabling healthcare systems to improve patient outcomes while strengthening public health responses to TB transmission. ( https://www.htfmarketinsights.com/report/4354561-drugresistant-tuberculosis-treatment-market ) “Our CE-IVD DeepChek ® Assay 13-Plex and BacterioChek software already provide laboratories with a robust and integrated solution for MTB drug resistance testing,” said Dr. Sofiane Mohamed, Head of R&D at ABL Diagnostics. “With our expanded research pipeline, including a 19-gene panel and a whole genome approach, we are extending this foundation to deliver more research tools for ongoing research, helping accelerate the discovery of new resistance pathways and informing next generation strategies for improved disease management and therapeutic innovation.” About ABL Diagnostics (ABLD) ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers: - Molecular polymerase chain reaction (PCR) detection – UltraGene, and - Genotyping by DNA sequencing – DeepChek ® . ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. An expanding portfolio of microbiology products: - HIV – Drug resistance testing, including a whole genome kit. - SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions. - Microbiome and taxonomy – 16s/18s RNA-based analyses. - Other viral and bacterial targets – Comprehensive molecular assays. Integrated Solutions - Real-time syndromic PCR tests - Nadis ® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis. - MediaChek ® – Clinical Sample Collection Kits. ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology. Dr Sayada ABL Diagnostics SA +33 7 83 64 68 50 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.